GlassScriptPhysician profile
Mira Lim
NPI 1194987628
$5,165.36
in general payments reported to CMS, 2019-2025
29 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $323 · 2021: $599 · 2022: $1,059 · 2023: $505 · 2024: $877 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,649 · Entertainment: $41.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,649.31 |
| Entertainment | $41.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,473.36 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Glaukos Corporation | $519.85 | 2020-2025 | Epioxa |
| Johnson & Johnson Surgical Vision, INC. | $312.73 | 2019-2025 | Tecnis Iol, Catalys System, Veritas Vision System |
| Mallinckrodt Hospital Products INC. | $296.52 | 2020-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $285.95 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $274.98 | 2019-2023 | |
| Dompe US, INC. | $204.90 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $204.60 | 2022-2024 | Tyrvaya, Ryzumvi, Tyrvaya |
| Bausch & Lomb Americas INC. | $157.28 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $140.31 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $138.28 | 2019-2021 | |
| Amgen INC. | $132.36 | 2024-2025 | Tepezza |
| Kedrion Biopharma, INC. | $117.83 | 2025 | Ryplazim |
| Harrow Eye, LLC | $114.43 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $111.43 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $103.79 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $84.06 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $83.44 | 2021-2022 | |
| Optos, INC. | $65.63 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $57.70 | 2023-2025 | Iyuzeh |
| Abbvie INC. | $50.13 | 2022-2023 | |
| Rxsight INC | $48.84 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $48.59 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $39.78 | 2024-2025 | Purified Cortrophin Gel |
| Beaver-Visitec International, INC. | $23.83 | 2021 | |
| Shire North American Group INC | $21.70 | 2019 | |
| Sight Sciences, INC. | $20.96 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.54 | 2020 | |
| Omeros Corporation | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mira Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.